Discovery of 6-chloro-2-trifluoromethyl-7-aryl-7H-imidazo[1,2-a]imidazol-3- ylmethylamines, a novel class of corticotropin-releasing factor receptor type 1 (CRF1R) antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 12, 2010, Pages 3669-3674

  Zuev, Dmitry ^a   Vrudhula, Vivekananda M ^a   Michne, Jodi A ^a   Dasgupta, Bireshwar ^a   Pin, Sokhom S ^a   Huang, Xiaohua Stella ^a   Wu, Dedong ^a,b   Gao, Qi ^a   Zhang, Jie ^a,c   Taber, Matthew T ^a   MacOr, John E ^a   Dubowchik, Gene M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b ASTRAZENECA   (United Kingdom)

^c SANOFI   (France)

Author keywords

Anxiety; Corticotropin releasing factor; Depression; Parallel synthesis

Indexed keywords

(6 CHLORO 2 TRIFLUOROMETHYL 7 ARYL 7H IMIDAZO[1,2 A]IMIDAZOL 3 YLMETHYL)DIALKYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY;

HUMANS; IMIDAZOLES; METHYLAMINES; PROTEIN BINDING; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77954214837     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.04.094     Document Type: Article

References (29)

1. M. Owens, and C.B. Nemeroff Pharmacol. Rev. 43 1991 425
2. D.E. Grigoriadis, M. Haddach, N. Ling, and J. Saunders Curr. Med. Chem. CNS Agents 1 2001 63
3. L.K. Takahashi Neurosci. Behav. Rev. 25 2001 627
4. J.W. Kasckow, D. Baker, and T.D. Geracioti Peptides 22 2001 845
5. F. Holsboer J. Psychiatr. Res. 33 1999 181
6. C.M. Banki, L. Karmasci, G. Bissette, and C.B. Nemeroff Eur. Neuropsychopharmacol. 2 1992 107
7. E.L. Webster, D.J. Torpy, I.J. Elenkov, and G.P. Chrousos Ann. N.Y. Acad. Sci. 840 1998 21
8. C.D. Dzierba, R.A. Hartz, and J.J. Bronson Ann. Rep. Med. Chem. 43 2008 3 23
9. M.B. Muller, and W. Wurst Trends Mol. Med. 8 2004 409 415
10. P.J. Gilligan, D.W. Robertson, and R. Zaczek J. Med. Chem. 43 2000 1641
11. L.F. Lee, F.M. Schleppnik, and R.K. Howe J. Heterocycl. Chem. 22 1985 1621
12. E.W. Byrnes, P.D. McMaster, E.R. Smith, M.R. Blair, R.N. Boyes, B.R. Duce, H.S. Feldman, G.H. Kronberg, B.H. Takman, and P.A. Tenthorey J. Med. Chem. 22 1979 1171
13. The assignment of structures of alkylation products 6a and 7a was made on the basis of the NOE studies. Particularly, a positive NOE effect was observed between the protons of the C4-methyl and N3-methylene groups in 7a. No such effect was seen in the studies with analog 6a:
14. The N1-regiospecificity of alkylation of 5b was evidenced by an X-ray crystallographic analysis of the mono TFA salt of compound 18, derived from intermediate 6b according to the following scheme: The X-ray crystal structure of 18 was deposited with Cambridge Crystallographic Data Centre (deposition number - CCDC 773714).
15. J.I. Levin, E. Turos, and S.M. Weinreb Synth. Commun. 12 1982 989
16. J. Malek Org. React. 36 1988 249
17. 24 reported in the literature, the dimerization of 11a to 12 is believed to proceed by the following mechanism:
18. This stabilizing effect of the trifluoromethyl group has been previously observed in related systems: see G.M. Dubowchik, J.A. Michne, D. Zuev, W. Schwartz, P.M. Scola, C. James, E. Ruediger, S. Pin, K.D. Burris, L. Balanda, Q. Gao, L. Fung, T. Fiedler, K.E. Browman, M.T. Taber, and J. Zhang Bioorg. Med. Chem. Lett. 13 2003 3997
19. X. Han, J.A. Michne, S.S. Pin, K.D. Burris, L.A. Balanda, L.K. Fung, T. Fiedler, K.E. Browman, M.T. Taber, J. Zhang, and G.M. Dubowchik Bioorg. Med. Chem. Lett. 15 2005 3870
20. Some of the utilized amines were commercially available, while the others were prepared according to the published procedure: see G.M. Dubowchik, J.A. Michne, and D. Zuev Bioorg. Med. Chem. Lett. 14 2004 3147
21. +).
22. 2O (10%)/TFA (0.1%); starting% B, 30; final% B, 100; flow rate 25 mL/min; gradient time, 20 min; end time, 25 min.
23. 2O (90%)/TFA (0.1%); starting% B, 0; final% B, 100; flow rate 4 mL/min; gradient time, 2 min; end time, 3 min.
24. 1R as determined by their ability to inhibit CRF stimulated cAMP production in IMR-32 cells.
25. M.M. Kamel, I. Nabih, M.E. Nasr, and M.M. Abbasi Pharmazie 40 1985 622
26. M. Abbasi, M. Nasr, H.H. Zoorob, and J.M. Michael J. Heterocycl. Chem. 15 1978 649
27. R.B. Frydman, S. Reil, and B. Frydman Biochemistry 10 1971 1154
28. W.J. Burke, W.A. Nasutavicus, and C. Weatherbee J. Org. Chem. 29 1964 407
29. K.D. Dieterich, and E.B. DeSouza Brain Res. 733 1996 113